SOURCE:; Sunshine Biopharma Inc.; Sunshine Biopharma Inc.

July 30, 2012 11:57 ET

CFA Commentary on Sunshine Biopharma, Inc. (OTCBB: SBFM)

Sunshine Biopharma, Inc. -- Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a

NEW YORK, NY--(Marketwire - Jul 30, 2012) - (, an investor research portal specializing in sector research including biotech and pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy Analytics LLC, on Sunshine Biopharma Inc. (OTCBB: SBFM) and its lead anti-cancer compound, Adva-27a. 

To read the full report:

About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.

About is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas:
Follow on Twitter!/Investorideas
Follow on Facebook

Sign up for the free investor news and biotech stock alerts

Visit the SBFM profile

Disclaimer/Disclosure: The is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th.

Patrick Murphy was compensated five hundred dollars for the CFA commentary article. 
BC Residents and Investor Disclaimer : Effective September 15 2008 -- all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

Contact Information